State-owned pharmaceutical firm Kimia Farma (KAEF) suffered loss attributable to owners of Rp102.7 billion in the first quarter (Q1) of 2024, against Rp0.38 billion in the corresponding period of 2023, due to higher costs. Sales grew 8.7% year on year (y/y) to Rp2.53 trillion in said period, while cost of goods sold rose 21.4% y/y to Rp1.7 trillion. Also, finance cost increased 19.8% y/y to Rp145.4 billion.
To subscribe please click here